이 보고서는 세계 망막 의약품 시장을 조사하여 시장 개요와 함께 삼출성 망막 질환에 대한 항VEGF 약물 및 기타 약물 및 약물 후보물질에 초점을 맞추고 당뇨병과 시력을 위협하는 망막 질환의 유병률에 대한 최신 추정치를 제시합니다. 또한 향후 5년간의 시장 성과 예측, 주요 미래 동향, 시장에 진입하는 40개 기업의 기업 개요 등을 제공합니다.
The "2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases" now focuses on anti-VEGFs and other drugs and drug candidates for exudative retinal diseases and gives updated estimates of the prevalence of diabetes and vision-threatening retinal diseases.
The new report analyzes treatment period trends and IVT injection shares by drug in the United States and Western Europe, reviews the cost per 30 days of wet AMD treatment in the United States, and evaluates more development-stage categories and companies.
The "2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases" analyzes the market for anti-VEGFs and other drugs for the treatment of exudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines the market's evolution, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 40 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.
The report explores a variety of topics intended to provide depth and context to the understanding of market dynamics in this ophthalmic segment. Our coverage includes:
The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, and biosimilars used for the treatment of exudative retinal diseases. The report also includes a separate forecast for sustained-drug-delivery devices in the treatment of such diseases.
The report delves into the development pipelines of eight categories of retinal pharmaceuticals: